A CLINICAL STUDY OF PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA

KARTHIK RAO¹, GURUKANTH RAO N², NAVIN PATIL³*, BALAJI O³, RAO NR⁴, JAYAPRAKASH RAO⁵, SATISH NAYAK⁶

¹Department of Internal Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. ²Consultant Physician, Aster Clinic, Dubai. ³Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. ⁴Consultant, Anugraha Medical Center, Udupi, Karnataka, India. ⁵Department of Medicine, Kasturba Medical College, Manipal, Karnataka, India. ⁶Department of Gastroenterology, Apollo, Chennai, Tamil Nadu, India. Email: navin903@gmail.com

ABSTRACT

Objective: Idiopathic thrombocytopenic purpura (ITP) is an immunological disorder characterized by the production of antibodies targeted toward platelets. Corticosteroids and intravenous immunoglobulins were the mainstay of immediate treatment after 1950s with splenectomy for more than 100 years remains the only option with curative potential. The aim of this study was to analyze the incidence, age and sex distribution among adults, various modes of presentation, correlation between thrombocytopenia and bleeding manifestations, and various modalities of treatment of ITP in a tertiary care hospital in India.

Methods: A prospective study included 40 cases of ITP admitted to Kasturba Medical College Hospital, Manipal, from November 2005 to March 2007. Patients above 14 years of age admitted with thrombocytopenia in this institution were screened based on detailed clinical history, physical examination, and laboratory investigations.

Results: The maximum incidence was in the 3rd decade of life accounting for 27.5% of the patients. Male-to-female ratio was 1:1.9 with female preponderance. Females in the 3rd decade had maximum incidence while males in the 4th decade have maximum incidence. The majority (12, 85.71%) of male patients and 15 (57.69%) female patients developed purpura during the course of disease. The mean count was 17.8×10⁹/L with range between 2.0×10⁹/L and 76×10⁹/L. Cutaneous bleeding spots were found to be associated with counts above 25000×10⁹/L and hematuria with lowest counts around 4000×10⁹/L. A number of 20 (50%) of the above 40 patients responded to corticosteroids alone and did not have any further relapse. Among the remaining patients, 3 (7.5%) had a relapse of symptoms within next 6 months and responded to repeat prednisolone started at 1 mg/kg. The remaining 8 (20%) patients were given steroids tapering dose with IV immune globulins for initial 5 days as therapy to which they responded.

Conclusion: Idiopathic thrombocytopenia is 1.9 times more common in females than males. Most common presentation is bleeding spots over body. Bleeding manifestations are more common with thrombocytopenia <30000/mm³. Corticosteroids are the mainstay in treatment. Complete remission is seen in up to 57.5% of the patients. Splenectomy is the second modality of treatment in ITP. Complete and sustained remission is seen 75% of patients.

Keywords: Idiopathic thrombocytopenic purpura, Splenectomy, Steroids, Purpura.

INTRODUCTION

Platelets are one of the three formed elements other than red and white blood cells which are seen in blood. These cells play an important role as far as hemostasis in the body is concerned. Platelets are susceptible to various forms of injury such as drugs, toxins, and viruses other than antibodies which destroy them by auto immune mechanism [1,2]. Thus, idiopathic thrombocytopenic purpura (ITP) can be considered as an immunological disorder that has received lot of attention in recent years. In 1735, a German physician Paul Gottlieb Werlhof described ITP nearly 10 decades before Victor Hugo’s published his novel Les misérables. ITP has an incidence of 6/100000, and the licensing of thrombopoietin mimetic agents has added a good paradigm to its management [3,4]. Corticosteroids and intravenous immunoglobulins were the mainstay of immediate treatment after 1950’s with splenectomy for more than 100 years remains the only option with curative potential. The center point in pathogenesis of this disorder is the production of antibodies targeted toward platelets as a result of derangement in immunological machinery of body wherein body fails to recognize these miniature cells as self. These antibodies get attached to platelets, which are destroyed and filtered off by the spleen. This results in decrease in number of platelets in peripheral blood giving rise to platelet manifestations [5].

There have been few numbers of studies carried out on ITP, but only a very few are in Indian subcontinent. This study was undertaken on ITP to study the incidence, age and sex distribution among adult, various modes of presentation, correlation between thrombocytopenia and bleeding manifestations, and various modalities of treatment instituted in this hospital.

METHODS

A prospective study consists of 40 cases of ITP admitted to Kasturba Medical College Hospital, Manipal, from November 2005 to March 2007. Ethical approval was taken from the institutional ethical board. Patients above 14 years of age admitted with thrombocytopenia in this institution were screened based on detailed clinical history, physical examination, and laboratory investigations. All patients were inpatients, in whom detailed workup was done in hospital.

Inclusion criteria*
1. Platelet count <1,00,000/mm³
2. Megakaryocyte hyperplasia on bone marrow examination
3. Positive antiplatelet antibody test.

* Peripheral blood examination, bone marrow examination, antplatelet antibody test, platelet factor 3 assay, antinuclear antibody, and human immunodeficiency virus by enzyme-linked immunosorbent assay were done to all patients.
Exclusion criteria*
1. History of recent ingestion of drugs known to cause thrombocytopenia
2. Clinical or laboratory evidence of microangiopathy or disseminated intravascular coagulation
3. Clinical evidence of chronic liver disease with portal hypertension or any evidence of hypersplenism
4. The presence of clinical evidence sufficient to diagnose connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus at presentation.

RESULTS
Forty patients of more than 14 years old admitted during the study were analyzed for age distribution. Patients varied from the second to 8th decades with the youngest patient being 15 years old and oldest being 75 years old. The maximum incidence was in the 3rd decade of life accounting for 27.5% of the patients (Table 1 and Fig. 1).

Of the total 40 patients, 14 were male and 26 were female. Male: female ratio was 1:1.9 with female preponderance (Table 2 and Fig. 2). Females in the 3rd decade had maximum incidence while males in the 4th decade have maximum incidence (Table 3 and Fig. 3). Among male patients, cutaneous bleeding spots including petechiae, purpura, and ecchymosis were the most common presenting symptoms. There was no predilection for any part of the body. The other presenting symptomes were bleeding gums, epistaxis, malena, and hematuria (Table 4 and Fig. 4).

Cutaneous bleeding spots (10, 38.46%) were the most common initial presenting symptom in females also. Menorrhagia (26.72%) was the initial presenting symptom in a significant percentage of patients in our study. Other less common presentations in females were bleeding gums, epistaxis, malena, hematuria, and hemoptysis (Table 5 and Fig. 5). The majority (12, 85.71%) of male patients and 15 (57.69%) female patients developed purpura during the course of disease. Other common manifestations were gum bleeding in males (28.57%) and females (34.61%), easy bruising in females (11.53%) and males (21.42%), epistaxis in females (15.38%), malena in females (11.53%), and hematuria in males (14.28%). Menorrhagia (42.30%) was the second most common presentation in females (Table 6 and Fig. 6). One male and female patient had mild splenomegaly with tip of spleen palpable 2 cm below the left costal margin without any clinical or investigational features (anti-nuclear antibody negative) to suggest a secondary cause for thrombocytopenia.

The mean count was 17.8×10^9/L with range between 2.0×10^9/L and 76×10^9/L. It was seen that 19 patients (42%) had platelets between 10 and 30×10^9/L with 14 patients having platelet count <10×10^9/L (Table 7). Correlation between the platelet count and clinical features of the patient at time of presentation (Table 8) was found and cutaneous bleeding spots were found to be associated with counts above 25000×10^9/L and hematuria with lowest counts around 4000×10^9/L.

All patients were started on prednisolone at 1 ml/kg as initial therapy. Of 40 patients, 20 (50%) responded to corticosteroids alone and did not have any further relapse. The corticosteroids were tapered over a period of 4-6 weeks and stopped. Among the remaining patients, 3 (7.5%) had a relapse of symptoms within next 6 months and responded to repeat prednisolone initiated at 1 mg/kg and tapered over 6 weeks. These patients responded completely and did not have any further symptoms. Another 4 (10%) patients who relapsed were started on dapsone along with steroids as therapy of which 1 (2.5%) patient was also started on danazol. All patients responded to therapy over a period of 6-8 weeks without further relapse. 2 (5%) patients were given steroids tapering dose with IV immune globulins for initial 5 days as therapy to which they responded (Table 9).

* Peripheral blood examination, bone marrow examination, antiplatelet antibody test, platelet factor 3 assay, antinuclear antibody, and human immunodeficiency virus by enzyme-linked immunosorbent assay were done to all patients.

Table 1: Distribution of cases according to age

| Age group (years) | Number of patients (%)
|------------------|------------------------
| 14-20            | 7 (17.5)               |
| 21-30            | 11 (27.5)              |
| 31-40            | 9 (22.5)               |
| 41-50            | 6 (15)                 |
| 51-60            | 4 (10)                 |
| >60              | 3 (7.5)                |

Table 2: Distribution of patients according to sex

| Sex       | Number (%) |
|-----------|------------|
| Males     | 14 (35)    |
| Females   | 26 (65)    |

Table 3: Distribution of cases according to sex and age of patients

| Age (years) | Number of patients | Males | Females |
|-------------|--------------------|-------|---------|
| 14-20       | 7                  | 4     | 3       |
| 21-30       | 11                 | 1     | 10      |
| 31-40       | 9                  | 5     | 4       |
| 41-50       | 6                  | 4     | 2       |
| 51-60       | 4                  | 1     | 3       |
| >60         | 3                  | 1     | 2       |

Fig. 1: Distribution of cases as per age

![Fig. 1: Distribution of cases as per age](image)

**Fig. 2: Sex-wise distribution of idiopathic thrombocytopenic purpura**

Among the remaining 13 (32.5%) patients who did not have an adequate response or patients who relapsed to initial medical therapy with steroids alone or along with immunosuppressive treatment, 8 (20%) had splenectomy done to which 6 had adequate response and complete remission. One of the two patients who did not have a response is dependent on low-dose prednisolone, having recurrence of symptoms on stopping steroids. The another patient with inadequate response to splenectomy is on therapy...
with danazol. Among the remaining 5 (12.5%) patients, 3 (7.5%) are steroid dependent on low-dose maintenance steroids with oral prednisolone. One patient is on dapsone therapy, another patient was initially started on dapsone, but it was discontinued due to development of methemoglobinemia and is on treatment with azathioprine.

**DISCUSSION**

ITP refers to thrombocytopenia in which apparent exogenous factors are lacking and in which diseases known to be associated with

**Table 4: Presenting symptoms of male patients**

| Symptom presentation   | Number of patients male (%) |
|------------------------|-----------------------------|
| Cutaneous bleeding spots | 8 (57.14)                   |
| Bleeding gums          | 3 (21.42)                   |
| Epistaxis              | 1 (7.14)                    |
| Malena                 | 1 (7.14)                    |
| Hematuria              | 1 (7.14)                    |

**Table 5: Symptoms female patients**

| Symptoms           | Number of patients (%) |
|--------------------|------------------------|
| Cutaneous bleeding spots | 10 (38.46)           |
| Menorrhagia        | 7 (26.92)              |
| Bleeding gums      | 5 (19.23)              |
| Epistaxis          | 1 (3.84)               |
| Malena             | 1 (3.84)               |
| Hematuria          | 1 (3.84)               |
| Hemoptysis         | 1 (3.84)               |

**Table 6: Common manifestations of ITP in male and females**

| Clinical features     | Males (%) | Females (%) |
|-----------------------|-----------|-------------|
| Purpura               | 12 (85.17)| 15 (57.69)  |
| Menorrhagia           | -         | 11 (42.30)  |
| Gum bleeding          | 4 (28.57) | 9 (34.61)   |
| Epistaxis             | -         | 4 (15.38)   |
| Easy bruisability     | 3 (21.42) | 3 (11.53)   |
| Malena                | -         | 3 (11.53)   |
| Hematuria             | 2 (14.28) | -           |

ITP: Idiopathic thrombocytopenic purpura

**Table 7: Platelet count in idiopathic thrombocytopenia**

| Platelet count×10⁹/L | Number of patients (%) |
|----------------------|------------------------|
| <10                  | 14 (35)                |
| 10-30                | 19 (47.5)              |
| 31-50                | 5 (12.5)               |
| 51-100               | 2 (5)                  |

**Table 8: Platelet count and clinical features at presentation**

| Clinical features     | Mean platelet count/mm³ |
|-----------------------|-------------------------|
| Cutaneous bleeding spots | 28432          |
| Gum bleeding          | 25770                    |
| Menorrhagia           | 9632                     |
| Easy bruisability     | 23333                    |
| Epistaxis             | 17500                    |
| Malena                | 9000                     |
| Hematuria             | 4000                     |

**Table 9: Modalities of treatment instituted**

| Treatment     | Number of patients |
|---------------|--------------------|
| Corticosteroids | 40                 |
| Splenectomy   | 8                  |
| Azathioprine  | 2                  |
| Danazol       | 5                  |
| Dapsone       | 9                  |
| IV Ig         | 2                  |

IV Ig: Intravenous immune globulin

**DISCUSSION**

ITP refers to thrombocytopenia in which apparent exogenous factors are lacking and in which diseases known to be associated with
secondary thrombocytopenia have been excluded. Females are affected 3-4 times more than males, and a seasonal fluctuation is noted with peak in spring and early summer and a nadir in winter. Acute ITP usually occurs in children <6 months and chronic ITP affects the adults. Pathophysiology of ITP includes inhibition of thrombopoiesis, platelet phagocytosis, antiplatelet antibody formation, antibody-mediated platelet destruction, and direct T-cell-mediated cytotoxicity against platelets in chronic ITP [5-15]. Clinically ITP presents as acute and chronic.

Acute ITP is usually sudden with history of infections preceding the bleeding by 2-3 weeks in 84% of cases [16]. Bleeding manifestations are usually mild [17] and intracranial hemorrhage in <1% of patients. It is usually self-limited with spontaneous remissions in 90% of cases [16]. Splenomegaly has been reported in 10% of patients [18]. The duration of disease ranges from few days to weeks with an average of 4-6 weeks [19].

Chronic ITP is insidious with long history of hemorrhagic symptoms of mild to moderate severity. Antecedent infections, fever, and splenic enlargement are uncommon with a fluctuating clinical course commonly seen. Spontaneous remissions are uncommon and are likely to be incomplete with cyclical or intermittent episodes of bleeding lasting few days to weeks. Relapses in some cases occur due to vaccination [20].

In this study, it was observed that ITP occurs over age group from 2nd to 8th decades with maximum incidence in the 3rd followed by the 4th decade. This observation is similar to that seen in other studies like those by Brown and Eliott [21], Portielje et al. [22], and Branehög et al. [23]. However, in a study conducted by Wong and Lee [24], the maximum incidence was in patients above 50 years followed by those in 4th decade. With respect to sex distribution, 65% of patients in this study were female with male:female ratio of 1:1.9, similar to incidence seen in studies conducted by Branehög et al. [23] and Wong and Lee [24].

Table 10: Comparison of symptoms of our study with other studies

| Symptom | Current study | Wong et al. |
|---------|---------------|-------------|
| Cutaneous bleeding | spots | 28.8×10^5/L | 30×10^5/L |
| Menorrhagia | 9.8×10^4 | 42×10^5 |
| Hematuria | 4×10^5 | 4.5×10^5 |
| Melaena | 9×10^4 | 16×10^4 |

Most common presenting symptom was bleeding spots over the body. Purpuric spots were distributed all over the body without predilection to any specific site. In studies conducted by Diffino et al. [25], Portielje et al. [22], and Wong and Lee [24], the most common mode of presentation was purpuric spots on body. Among the male patients, the second most presentation was bleeding gums whereas among female patients it was menorrhagia. Wong and Lee [24] also reported menorrhagia as a common presenting complaint in females. Doan et al. [19] had reported one patient whose only symptom was menorrhagia. In this study, there were three patients whose only symptom was menorrhagia. Lacey and Penner [26] had reported a case with history on intracranial bleed with no history of bleeding manifestation before that. A similar case was reported by Wong and Lee [24]. However, in the present study, no patient presented with intracranial bleed.

Splenomegaly is rarely found in patients with ITP. However, spleen may be palpable in 5% of patients as described by Doan et al. [19]. In the current study, 2 patients had mild splenomegaly. An attempt was made to correlate between the platelet count and clinical feature at presentation. Mean platelet counts varied from 28856/mm^3 in patients with purpura to 4000/mm^3 in patients with hematuria. This was similar to study conducted by Wong and Lee [24]. However, patients presented with menorrhagia at a higher platelet count in that study (Table 10).

Complete remission to steroids was observed in 57.5% of the patients. Studies conducted by Portielje et al. [22] and Wong and Lee [24] revealed remission in 67.7% and 46.7% of patients, respectively. About 75% of patients in the current study had sustained remission. Similar results were obtained in studies by Portielje et al. [22] with remission of 75% and that conducted by Wong and Lee [24] with remission of 64.9%.

CONCLUSION

Idiopathic thrombocytopenia is 1.9 times more common in females than males. Adults with ITP present between the second and 8th decade with maximum incidence in the 3rd and 4th decades of life. Patients present with various hemorrhagic manifestations. Most common presentation is bleeding spots over body. Subsequently, they may develop symptoms of bleeding at other sites such as menorrhagia, epistaxis, melaena, and hematuria. Splenic enlargement is very common in ITP. However, spleen may be just palpable in 5% of patients with this disorder. Severity of bleeding manifestations corresponds to degree of thrombocytopenia. Bleeding manifestations are more common with thrombocytopenia <30000/mm^3. Corticosteroids are the mainstay in treatment. Complete remission is seen in up to 57.5% of the patients. Splenectomy is the second modality of treatment in ITP. Complete and sustained remission is seen 75% of patients. Patients who do not have an adequate response can be treated with either immunosuppressive drugs or maintenance dose of corticosteroids.

REFERENCES

1. Lee SY, Chary M, Salehi I, Bansal R. Immune-mediated aludiminab-induced thrombocytopenia for the treatment of ulcerative colitis. Int J Pharm Sci 2015;7(7):456-8.
2. Balaji O, Patil N, Avinash A, Tilak A. Cefuroxime-induced thrombocytopenia: It’s just not in the ring? Asian J Pharm Clin Res 2016;9(5):1-2.
3. Rao VK. ITP: Hematologists’ Cossette from Les Miserables. Blood 2013;121(11):1928-30.
4. Segal JB, Powe NR. Correlation of immune thrombocytopenia: Analyses of administrative data. J Thromb Haemost 2006;4(11):2377-83.
5. Leung LL. Role of thrombospondin in platelet aggregation. J Clin Invest 1984;74(5):1764.
6. Roth GJ. Developing relationships: Arterial platelet adhesion, glycoprotein IB, and leucine-rich glycoproteins. Blood 1991;77(1):5-19.
7. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Infeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocyteopoiesis in vitro. Blood 2003;102(3):887-95.
8. McMillan R, Wang L, Tomer A, Nichol J, Piscillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103(4):1364-9.
9. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002;100(2):728-30.
10. Bussel JB, Kuter DJ, George JN, Aledort LM, Lichten AE, Lyons RM, et al. Long-term dosing of AMG 531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura. Blood 2005;106(11):220.
11. McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003;1(3):485-91.
12. Berchtold P, Beardsley D, Fujisawa K, Kaplan C, Lipp E, Mowat-Kopp MC, et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 1997;96(3):477-83.
13. Fabris F, Scandellari R, Ruzzon E, Randi ML, Luzzatto G, Girolami A. Platelet-associated autoantibodies as detected by a solid-phase modified

376
antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 2004;103(12):4562-4.
14. Webster ML, Sayeh E, Crow M, Chen P, Nieswandt B, Freedman J, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbα antibodies. Blood 2006;108(3):943-6.
15. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291(5503):484-6.
16. Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. J Pediatr 1966;68(6):971-9.
17. Kurtzberg J, Stockman 3rd JA. Idiopathic autoimmune thrombocytopenic purpura. Adv Pediatr 1993;41:111-34.
18. McWilliams NB, Maurer HM. Acute idiopathic thrombocytopenic purpura in children. Am J Hematol 1979;7(1):87-96.
19. Doan CA, Bouroncle BA, Wiseman BK. Idiopathic and secondary thrombocytopenic purpura: Clinical study and evaluation of 381 cases over a period of 28 years. Ann Intern Med 1960;53(5):861-76.
20. Kellon JG. Vaccination-associated relapse of immune thrombocytopenia. JAMA 1981;245(4):369-71.
21. Brown DN, Elliott HE. The result of splenectomy in thrombocytopenic purpura. JAMA 1986;291(11):1781.
22. Portielje JE, Westendorp RG, Kluij-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97(9):2549-54.
23. Branelt J, Kutti J, Weinfeld A. Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 1974;27(1):127-43.
24. Wong GC, Lee JH. A study of idiopathic thrombocytopenic purpura (ITP) patients over a ten-year period. Ann Acad Med Singapore 1998;27:789-93.
25. Difino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura: Clinical findings and response to therapy, Am J Med 1980;69(3):430-42.
26. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977;3(3):160-74.
27. Laros RK, Penner JA. Refractory thrombocytopenic purpura treated successfully with cyclophosphamide. JAMA 1971;215(3):445-9.
28. Caplan SN, Berkman EM. Immunosuppressive therapy of idiopathic thrombocytopenic purpura. Med Clin N Am 1976;60(5):971-86.